India has become one of the first countries to introduce cheaper, generic brands of weight loss drugs like Ozempic and Wegovy, but health professionals warn a lack of regulation and oversight is causing problems.
Personalise the news and
stay in the know
Emergency
Backstory
Newsletters
With India’s semaglutide patent expiring on 20 March, about 50 branded generics are expected to enter the market.
NEW DELHI: India’s Health Ministry warned on Tuesday of the unregulated use of weight-loss drugs, as cheap generic versions of…
India’s health ministry warned Tuesday of the risks of unregulated use of weight-loss drugs, as low-cost generic versions hit the…
India's market for cheaper anti-obesity drugs has surged tenfold. While demand is high, especially among those with diabetes,…
The landscape of India's anti-obesity drug market has reached a point of refinement. While there are affordable generic options,…
Last week’s expiry of the patent for semaglutide—the active ingredient in Novo Nordisk’s blockbuster drugs Wegovy and Ozmepic…
